Publications by authors named "Mat Davis"

Claim this Profile
B
Behavioral and transcriptomic effects of a novel cannabinoid on a rat valproic acid model of autism.
Sally Loomis, Diogo G Silva, Ranjev Savopoulos, Jackie Cilia, Jennifer Li, Mat D Davis

Neuropharmacology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Risk of New-Onset Hypertension in Patients With Narcolepsy Initiating Sodium Oxybate: A Real-World Study.
Rami H Ben-Joseph, Virend K Somers, Jed Black, Ralph B D'Agostino, Mat Davis

Mayo Clin Proc· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of three times weekly dosing regimen of glatiramer acetate in relapsing multiple sclerosis patients: Seven-year results of the Glatiramer Acetate Low-frequency Administration (GALA) open-label extension study.
Peter Rieckmann, Robert Zivadinov, Alexey Boyko, Krzysztof Selmaj, Jessica K Alexander, Mat D Davis

Mult Scler J Exp Transl Clin· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
Hubert H Fernandez, David Stamler, Mat D Davis, Stewart A Factor, Robert A Hauser

J Neurol Neurosurg Psychiatry· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
Nicholas G LaRocca, Lynn D Hudson, Richard Rudick, Dagmar Amtmann, Laura Balcer, Mat D Davis

Mult Scler· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining agreement using rater characteristics.
Mat D Davis, Jeffrey Joseph

J Biopharm Stat· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Karen E Anderson, David Stamler, Mat D Davis, Stewart A Factor, Robert A Hauser

Lancet Psychiatry· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.
Marcus W Koch, Gary R Cutter, Gavin Giovannoni, Bernard M J Uitdehaag, Jerry S Wolinsky, Mat D Davis

Neurol Neuroimmunol Neuroinflamm· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Omar Khan, Peter Rieckmann, Alexey Boyko, Krzysztof Selmaj, Natalia Ashtamker, Mat D Davis

Mult Scler· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
Hubert H Fernandez, Stewart A Factor, Robert A Hauser, Joohi Jimenez-Shahed, William G Ondo, Charles Davis, Mat D Davis

Neurology· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study.
Mat D Davis, Natalia Ashtamker, Joshua R Steinerman, Volker Knappertz

Neurol Neuroimmunol Neuroinflamm· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Robert Zivadinov, Michael G Dwyer, Deepa P Ramasamy, Mat D Davis, Joshua R Steinerman

J Neuroimaging· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the Multi-Ethnic Study of Atherosclerosis.
Emil M Degoma, Mat D Davis, Richard L Dunbar, Emile R Mohler, Philip Greenland

Atherosclerosis· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.
Reisa A Sperling, Keith A Johnson, P Murali Doraiswamy, Eric M Reiman, Adam S Fleisher, Mat D Davis

Neurobiol Aging· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
P Murali Doraiswamy, Reisa A Sperling, R Edward Coleman, Keith A Johnson, Eric M Reiman, Mat D Davis

Neurology· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis